RLAY241220C10000
- 0.04
- 0.000.00%
Relay Therapeutics Newsroom
We Think Relay Therapeutics (NASDAQ:RLAY) Needs To Drive Business Growth Carefully
Relay Therapeutics Insider Sold Shares Worth $500,000, According to a Recent SEC Filing
JMP Securities Reiterates Market Outperform on Relay Therapeutics, Maintains $21 Price Target
Relay Therapeutics Analyst Ratings
TD Cowen Maintains Relay Therapeutics(RLAY.US) With Buy Rating
Jefferies Maintains Relay Therapeutics(RLAY.US) With Buy Rating, Raises Target Price to $17
Jefferies Reaffirms Their Buy Rating on Relay Therapeutics (RLAY)
A Quick Look at Today's Ratings for Relay Therapeutics(RLAY.US), With a Forecast Between $17 to $21
Relay Therapeutics (RLAY) Gets a Buy From Barclays
Express News | Relay Therapeutics Inc : Jefferies Raises Target Price to $17 From $16
Relay Therapeutics' RLY-2608: Promising Data and Strategic Plans Reinforce Buy Rating
Express News | Relay Therapeutics Shares up 7.5% Premarket After Co Reports Interim Data for Breast Cancer Drug
Relay Therapeutics' RLY-2608 Shows 11.4-Month Survival in Breast Cancer Patients in Latest Clinical Trial Results
Express News | Relay Therapeutics Inc -Data Support Planned Initiation of 2L Pivotal Study in 2025
Express News | Relay Therapeutics Inc: 39% Confirmed Orr Across All Patients & 67% in Patients With Kinase Mutations at Rp2D
Relay Therapeutics Announces Updated Interim Data for RLY-2608 + Fulvestrant Demonstrating Continued Maturation of Clinically Meaningful Progression Free Survival
Express News | Relay Therapeutics Announces Updated Interim Data for Rly-2608 + Fulvestrant Demonstrating Continued Maturation of Clinically Meaningful Progression Free Survival
Relay Therapeutics to Present Updated Clinical Data on RLY-2608 in HR+/HER2- Breast Cancer at 2024 San Antonio Breast Cancer Symposium
After Plunging -30.29% in 4 Weeks, Here's Why the Trend Might Reverse for Relay Therapeutics (RLAY)
H.C. Wainwright Maintains Relay Therapeutics(RLAY.US) With Buy Rating, Cuts Target Price to $16